These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22408249)

  • 1. Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.
    Laussmann MA; Passante E; Hellwig CT; Tomiczek B; Flanagan L; Prehn JH; Huber HJ; Rehm M
    J Biol Chem; 2012 Apr; 287(18):14402-11. PubMed ID: 22408249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
    Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
    Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
    J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
    Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
    Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
    Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
    Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
    Thorpe JA; Christian PA; Schwarze SR
    Prostate; 2008 Feb; 68(2):200-9. PubMed ID: 18076022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
    Sayers TJ; Murphy WJ
    Cancer Immunol Immunother; 2006 Jan; 55(1):76-84. PubMed ID: 15864587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin as a proteasome inhibitor. Is there any clinical evidence?
    Vriend J; Reiter RJ
    Life Sci; 2014 Oct; 115(1-2):8-14. PubMed ID: 25219883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
    Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
    Kahana S; Finniss S; Cazacu S; Xiang C; Lee HK; Brodie S; Goldstein RS; Roitman V; Slavin S; Mikkelsen T; Brodie C
    Cell Signal; 2011 Aug; 23(8):1348-57. PubMed ID: 21440622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
    Seki N; Toh U; Sayers TJ; Fujii T; Miyagi M; Akagi Y; Kusukawa J; Kage M; Shirouzu K; Yamana H
    Mol Cancer Ther; 2010 Jun; 9(6):1842-51. PubMed ID: 20515944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
    Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
    Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
    Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
    Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
    Yang TM; Barbone D; Fennell DA; Broaddus VC
    Am J Respir Cell Mol Biol; 2009 Jul; 41(1):14-23. PubMed ID: 19097992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.